BioSpace News Archive

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022.

20/20 Imaging, a division of Konica Minolta Healthcare Americas, Inc., announces the FDA clearance of the Chiropractic Straight Arm (CSA) system with Dynamic Digital Radiography (DDR). DDR is Konica Minolta’s revolutionary X-ray technology enabling the visualization of anatomy in motion so clinicians can interpret the dynamic interaction of anatomical structures, such as tissue and bone, with physiological changes over time.

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and its global agriculture partners continue to drive MustGrow’s organic mustard-derived crop protection and food preservation technology forward through field trials, development work and regulatory approval strategies in key global agricultural regions.

Terumo Cardiovascular, a global leader in medical devices for cardiac and vascular surgery, marked the opening of its newest manufacturing plant in La Lima, Cartago, Costa Rica.

(“PathogenDx” or “Company”), a leader in next-generation microarray technology for better health and safety, launched a new breakthrough virus detection technology - Phytox - to help curb the spread of new and existing plant-born pathogens, which are currently on the rise.

LumiThera Inc. is proud to announce that the AdaptDx Pro® has been recognized as one of Fast Company’s 2022 Innovation and Design Award honorees.

AcelaBio (US) Inc., a contract research organization delivering histopathology and precision medicine laboratory services for global clinical trials, achieved its accreditation by the College of American Pathologists (CAP).

As per the latest professional survey report on the global alpha 1 antitrypsin deficiency treatment market by the Transparency Market Research, the industry is anticipated to rise at a significant growth rate of 10.1 % over the forecast period, i.e. 2019 to 2027.

GigaGen Inc. announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.

Antisense and RNAi therapeutics the new class of drugs that apply their impact either by hushing a piece of RNA using short meddling RNAs (siRNAs) or microRNAs (miRNAs) which is engaged with causing the sickness or instigates the debasement of designated mRNA by RNase and in this manner decreasing the interpretation of unfortunate protein